NEWTOWN, Pa., June 05, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported that three new clinics have been authorized to provide PoNS Treatment™ in Canada, giving Canadians broader regional access to the Company’s innovative treatment. The new clinics join the current roster of existing clinics authorized to provide the PoNS Treatment, including Neurotherapy Montreal and Surrey Neuroplasticity Clinic.
Since opening the first authorized clinic, Neurotherapy Montreal in Quebec, in December 2018, and the second authorized clinic, Surrey Neuroplasticity Clinic in British Columbia, in February 2019, the Company has made it a priority to make the PoNS accessible to patients from coast-to-coast. Joining the existing PoNS authorized neurological rehabilitation clinics are Advantage 4 Athletes Training Center and Therapy Clinic in Markham, Ontario; Synaptic Spinal Cord Injury and Neuro Rehabilitation Centre in Calgary, Alberta; and Apollo South Physical Therapy Centre in Ottawa, Ontario.
The clinics were selected by Heuro Canada Inc. (“Heuro”), a company organized pursuant to the strategic alliance agreement between Helius and Health Tech Connex, Inc., to develop a system of clinics authorized to provide PoNS Treatment through the Heuro Program in Canada. Heuro is focused on improving the quality of life of Canadians experiencing chronic balance deficits caused by mild-to-moderate traumatic brain injuries and is proud to now offer the Heuro Program featuring PoNS Treatment in five of Canada’s largest census metropolitan areas.
“We are pleased that the strategy to accelerate expansion plans in Canada has driven the further development of the clinic system authorized to provide PoNS Treatment,” said Philippe Deschamps, Chief Executive Officer of Helius. “Patients who have had mild-to-moderate traumatic brain injuries are often not able to travel long distances and now, with a presence in Montreal, Vancouver, Toronto, Calgary and Ottawa, over 50% of Canadians will have direct local access to PoNS Treatment,” continued Deschamps.
The PoNS Treatment is an innovative, non-invasive treatment which combines the use of the PoNS™ device with targeted physical therapy. The PoNS device is authorized in Canada for the acute treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury, and is to be used in conjunction with physical therapy.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS™). For more information, visit www.heliusmedical.com.
About the PoNS Device and PoNS Treatment
The Portable Neuromodulation Stimulator (PoNS) is a licensed class II, noninvasive, medical device in Canada intended for use as an acute treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with physical therapy. The device is limited to prescription use. The PoNS is an investigational medical device in the United States, the European Union (“EU”), and Australia (“AUS”), and it is currently under review for clearance by an EU Notified Body and the AUS Therapeutic Goods Administration. PoNS Treatment™ is currently not commercially available in the United States, the European Union or Australia.
Investor Relations Contact:
Westwicke Partners on behalf of Helius Medical Technologies, Inc.
Mike Piccinino, CFA
Cautionary Disclaimer Statement:
Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as “believe,” “continue,” “look forward,” “will” and similar expressions. Such forward-looking statements include, among others, statements regarding the Company’s business and commercialization initiatives and objectives, future clinical and regulatory development plans for the PoNS and the potential regulatory clearance of the PoNS device.
There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the uncertainties associated with the regulation of commercially available medical devices in Canada, including Health Canada’s ongoing assessment of post-market data, the clinical development, regulatory submission and approval process in the United States, the European Union and Australia, as well as the Company’s capital requirements needed to achieve its business objectives and other risks detailed from time to time in the filings made by the Company with securities regulators, and including the risks and uncertainties about the Company’s business described in the “Risk Factors” sections of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, its Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com.
The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.
The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.